Suppr超能文献

美国药物过敏登记处(USDAR)即时药物反应分级量表。

United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions.

机构信息

Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Tex.

Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, Tenn; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tenn.

出版信息

J Allergy Clin Immunol. 2023 Dec;152(6):1581-1586. doi: 10.1016/j.jaci.2023.08.018. Epub 2023 Aug 29.

Abstract

BACKGROUND

There is no accepted grading system classifying the severity of immediate reactions to drugs.

OBJECTIVE

The purpose of this article is to present a proposed grading system developed through the consensus of drug allergy experts from the United States Drug Allergy Registry (USDAR) Consortium.

METHODS

The USDAR investigators sought to develop a consensus severity grading system for immediate drug reactions that is applicable to clinical care and research.

RESULTS

The USDAR grading scale scores severity levels on a scale of 0 to 4. A grade of no reaction (NR) is used for patients who undergo challenge without any symptoms or signs, and it would confirm a negative challenge result. A grade 0 reaction is indicative of primarily subjective complaints that are commonly seen with both historical drug reactions and during drug challenges, and it would suggest a low likelihood of a true drug allergic reaction. Grades 1 to 4 meet the criteria for a positive challenge result and may be considered indicative of a drug allergy. Grade 1 reactions are suggestive of a potential immediate drug reaction with mild symptoms. Grade 2 reactions are more likely to be immediate drug reactions of moderate severity. Grade 3 reactions have features suggestive of a severe allergic reaction, whereas grade 4 reactions are life-threatening reactions such as anaphylactic shock and fatal anaphylaxis.

CONCLUSION

This proposed grading schema for immediate drug reactions improves on prior schemata by being developed specifically for immediate drug reactions and being easy to implement in clinical and research practice.

摘要

背景

目前尚无被广泛接受的药物过敏即时反应严重程度分级系统。

目的

本文旨在介绍一种通过美国药物过敏注册中心(USDAR)专家共识制定的新的即时药物过敏反应严重程度分级系统。

方法

USDAR 研究人员旨在开发一种适用于临床和研究的即时药物过敏反应严重程度分级系统。

结果

USDAR 分级量表的严重程度评分为 0-4 级。无反应(NR)等级用于接受挑战但无任何症状或体征的患者,这将确认阴性挑战结果。0 级反应表示主要是主观抱怨,在药物过敏反应和药物挑战中均常见,这表明发生真正药物过敏反应的可能性较低。1-4 级符合阳性挑战结果的标准,可能被认为提示药物过敏。1 级反应提示有潜在的即时药物过敏反应,症状轻微。2 级反应更可能是中度严重的即时药物过敏反应。3 级反应具有严重过敏反应的特征,而 4 级反应则是危及生命的过敏反应,如过敏性休克和致命性过敏性休克。

结论

该即时药物过敏反应分级方案优于既往方案,因为它是专为即时药物过敏反应而制定的,且易于在临床和研究实践中实施。

相似文献

1
United States Drug Allergy Registry (USDAR) grading scale for immediate drug reactions.
J Allergy Clin Immunol. 2023 Dec;152(6):1581-1586. doi: 10.1016/j.jaci.2023.08.018. Epub 2023 Aug 29.
2
A Guide to Pediatric Antibiotic Allergy Testing: A Report From the US Drug Allergy Registry.
J Allergy Clin Immunol Pract. 2025 May;13(5):1018-1026.e1. doi: 10.1016/j.jaip.2024.12.036. Epub 2025 Jan 2.
3
Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests.
Pediatr Allergy Immunol. 2011 Jun;22(4):411-8. doi: 10.1111/j.1399-3038.2011.01169.x. Epub 2011 Mar 30.
4
Allergy to beta-lactam antibiotics in children.
Pediatrics. 1999 Oct;104(4):e45. doi: 10.1542/peds.104.4.e45.
5
Drug allergy in older adults: A study from the United States Drug Allergy Registry.
Ann Allergy Asthma Immunol. 2023 Nov;131(5):628-636.e2. doi: 10.1016/j.anai.2023.07.024. Epub 2023 Aug 7.
6
Risk Factors of Challenge-Proven Beta-Lactam Allergy in Children with Immediate and Non-Immediate Mild Cutaneous Reactions.
Int Arch Allergy Immunol. 2023;184(6):539-549. doi: 10.1159/000529084. Epub 2023 Mar 1.
8
Clinical Relevance of Specific IgE in Penicillin Allergy Investigation.
Int Arch Allergy Immunol. 2025;186(4):303-310. doi: 10.1159/000541243. Epub 2024 Oct 25.
9
[Hypersensitivity reactions to beta-lactam antibiotics].
Rev Med Interne. 2017 Nov;38(11):737-748. doi: 10.1016/j.revmed.2017.06.020. Epub 2017 Jul 25.
10
Clinical presentation and time course in hypersensitivity reactions to beta-lactams.
Allergy. 2007 Aug;62(8):872-6. doi: 10.1111/j.1398-9995.2007.01463.x.

引用本文的文献

2
Role of anti-IgE in immediate drug allergy.
J Allergy Clin Immunol. 2025 Jan;155(1):84-86. doi: 10.1016/j.jaci.2024.09.021. Epub 2024 Oct 2.
3
A Skin Testing Strategy for Non-IgE-Mediated Reactions Associated With Vancomycin.
J Allergy Clin Immunol Pract. 2024 Nov;12(11):3025-3033.e6. doi: 10.1016/j.jaip.2024.07.028. Epub 2024 Aug 6.
4
First-Line Antituberculosis Drug Challenge Reactions in Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in an HIV Endemic Setting.
J Allergy Clin Immunol Pract. 2024 Oct;12(10):2798-2808.e12. doi: 10.1016/j.jaip.2024.05.045. Epub 2024 Jun 7.

本文引用的文献

2
Racial Disparity in Oxygen Saturation Measurements by Pulse Oximetry: Evidence and Implications.
Ann Am Thorac Soc. 2022 Dec;19(12):1951-1964. doi: 10.1513/AnnalsATS.202203-270CME.
3
Drug allergy: A 2022 practice parameter update.
J Allergy Clin Immunol. 2022 Dec;150(6):1333-1393. doi: 10.1016/j.jaci.2022.08.028. Epub 2022 Sep 17.
5
Updating the CoFAR Grading Scale for Systemic Allergic Reactions in Food Allergy.
J Allergy Clin Immunol. 2022 Jun;149(6):2166-2170.e1. doi: 10.1016/j.jaci.2021.12.789. Epub 2022 Jan 11.
7
Severity grading system for acute allergic reactions: A multidisciplinary Delphi study.
J Allergy Clin Immunol. 2021 Jul;148(1):173-181. doi: 10.1016/j.jaci.2021.01.003. Epub 2021 Jan 19.
8
Patient Characteristics and Concerns about Drug Allergy: A Report from the United States Drug Allergy Registry.
J Allergy Clin Immunol Pract. 2020 Oct;8(9):2958-2967. doi: 10.1016/j.jaip.2020.08.018. Epub 2020 Aug 24.
9
Drug-associated inducible laryngeal obstruction complicating penicillin allergy testing.
Ann Allergy Asthma Immunol. 2020 Nov;125(5):599-600. doi: 10.1016/j.anai.2020.06.031. Epub 2020 Jun 26.
10
Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
Ann Allergy Asthma Immunol. 2020 Sep;125(3):325-333.e1. doi: 10.1016/j.anai.2020.04.017. Epub 2020 Apr 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验